This site is intended for U.S. healthcare professionals only.

Contact Us

If you have any questions or inquiries about KENGREAL® (cangrelor) or our other products, please use the information below to contact us.

Contact Chiesi USA, Inc.

Mail:
Chiesi USA, Inc.
1255 Crescent Green Drive
Suite 250
Cary, NC 27518

Phone:
1-888-466-6505

Medical Information

To request specific medical information about KENGREAL® or to report adverse events or product complaints, contact the Medical Information Department.

Adverse events may also be reported to the FDA’s MedWatch Program at 1-800-FDA-1088.

Mail:
Chiesi USA, Inc.
1255 Crescent Green Drive
Suite 250
Cary, NC 27518

Phone:
1-888-661-9260

Fax:
1-866-443-3092

Email:
US.Medical@chiesi.com

Important Safety Information

KENGREAL® (cangrelor) for Injection is contraindicated in patients with significant active bleeding.

KENGREAL® is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.

Drugs that inhibit platelet P2Y12 function, including KENGREAL®, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREAL® than with clopidogrel. Bleeding complications with KENGREAL® were consistent across a variety of clinically important subgroups. Once KENGREAL® is discontinued, there is no antiplatelet effect after an hour.

The most common adverse reaction is bleeding.

Please see full prescribing information.

www.kengreal.com

This site is intended for U.S. healthcare professionals. If you are a U.S. healthcare professional, click OK to continue.

Cancel
Ok